Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

The 2'-Trifluoromethyl Analogue of Indomethacin Is a Potent and Selective COX-2 Inhibitor.

Blobaum AL, Uddin MJ, Felts AS, Crews BC, Rouzer CA, Marnett LJ.

ACS Med Chem Lett. 2013 May 9;4(5):486-490. Epub 2013 Mar 25.

2.

Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.

Riendeau D, Percival MD, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Falgueyret JP, Ford-Hutchinson AW, Gordon R, Greig G, Gresser M, Guay J, Kargman S, Léger S, Mancini JA, O'Neill G, Ouellet M, Rodger IW, Thérien M, Wang Z, Webb JK, Wong E, Chan CC, et al.

Br J Pharmacol. 1997 May;121(1):105-17.

3.

Molecular basis of the time-dependent inhibition of cyclooxygenases by indomethacin.

Prusakiewicz JJ, Felts AS, Mackenzie BS, Marnett LJ.

Biochemistry. 2004 Dec 14;43(49):15439-45.

PMID:
15581355
4.

Pharmacology of a selective cyclooxygenase-2 inhibitor, HN-56249: a novel compound exhibiting a marked preference for the human enzyme in intact cells.

Berg J, Fellier H, Christoph T, Kremminger P, Hartmann M, Blaschke H, Rovensky F, Towart R, Stimmeder D.

Naunyn Schmiedebergs Arch Pharmacol. 2000 Apr;361(4):363-72.

PMID:
10763850
5.

ER-34122, a novel dual 5-lipoxygenase/cyclooxygenase inhibitor with potent anti-inflammatory activity in an arachidonic acid-induced ear inflammation model.

Horizoe T, Nagakura N, Chiba K, Shirota H, Shinoda M, Kobayashi N, Numata H, Okamoto Y, Kobayashi S.

Inflamm Res. 1998 Oct;47(10):375-83.

PMID:
9831321
6.

Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors.

Kalgutkar AS, Crews BC, Rowlinson SW, Marnett AB, Kozak KR, Remmel RP, Marnett LJ.

Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):925-30.

7.

Anti-inflammatory activity of myricetin-3-O-beta-D-glucuronide and related compounds.

Hiermann A, Schramm HW, Laufer S.

Inflamm Res. 1998 Nov;47(11):421-7.

PMID:
9865500
8.

Trifluoromethyl fluorocoxib a detects cyclooxygenase-2 expression in inflammatory tissues and human tumor xenografts.

Uddin MJ, Crews BC, Huda I, Ghebreselasie K, Daniel CK, Marnett LJ.

ACS Med Chem Lett. 2014 Jan 23;5(4):446-50. doi: 10.1021/ml400485g. eCollection 2014 Apr 10.

9.

Ester and amide derivatives of the nonsteroidal antiinflammatory drug, indomethacin, as selective cyclooxygenase-2 inhibitors.

Kalgutkar AS, Marnett AB, Crews BC, Remmel RP, Marnett LJ.

J Med Chem. 2000 Jul 27;43(15):2860-70.

PMID:
10956194
10.

Evaluation of COX-1/COX-2 selectivity and potency of a new class of COX-2 inhibitors.

Gierse J, Nickols M, Leahy K, Warner J, Zhang Y, Cortes-Burgos L, Carter J, Seibert K, Masferrer J.

Eur J Pharmacol. 2008 Jun 24;588(1):93-8. doi: 10.1016/j.ejphar.2008.03.057. Epub 2008 Apr 6.

PMID:
18457826
11.

Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.

Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, Gordon R, Gresser M, Guay J, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O'Neill GP, Ouellet M, Patrick D, Percival MD, Perrier H, Prasit P, Rodger I, et al.

J Pharmacol Exp Ther. 1999 Aug;290(2):551-60.

13.

Molecular determinants for the selective inhibition of cyclooxygenase-2 by lumiracoxib.

Blobaum AL, Marnett LJ.

J Biol Chem. 2007 Jun 1;282(22):16379-90. Epub 2007 Apr 12.

14.

Conservative Secondary Shell Substitution In Cyclooxygenase-2 Reduces Inhibition by Indomethacin Amides and Esters via Altered Enzyme Dynamics.

Konkle ME, Blobaum AL, Moth CW, Prusakiewicz JJ, Xu S, Ghebreselasie K, Akingbade D, Jacobs AT, Rouzer CA, Lybrand TP, Marnett LJ.

Biochemistry. 2016 Jan 19;55(2):348-59. doi: 10.1021/acs.biochem.5b01222. Epub 2015 Dec 31.

15.

Structural basis of enantioselective inhibition of cyclooxygenase-1 by S-alpha-substituted indomethacin ethanolamides.

Harman CA, Turman MV, Kozak KR, Marnett LJ, Smith WL, Garavito RM.

J Biol Chem. 2007 Sep 21;282(38):28096-105. Epub 2007 Jul 26.

16.

Cyclooxygenases 1 and 2 contribute to peroxynitrite-mediated inflammatory pain hypersensitivity.

Ndengele MM, Cuzzocrea S, Esposito E, Mazzon E, Di Paola R, Matuschak GM, Salvemini D.

FASEB J. 2008 Sep;22(9):3154-64. doi: 10.1096/fj.08-108159. Epub 2008 May 22.

PMID:
18497304
17.

Pharmacological analysis of cyclooxygenase-1 in inflammation.

Smith CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A, Talley JJ, Masferrer JL, Seibert K, Isakson PC.

Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13313-8.

18.

The interaction of arginine 106 of human prostaglandin G/H synthase-2 with inhibitors is not a universal component of inhibition mediated by nonsteroidal anti-inflammatory drugs.

Greig GM, Francis DA, Falgueyret JP, Ouellet M, Percival MD, Roy P, Bayly C, Mancini JA, O'Neill GP.

Mol Pharmacol. 1997 Nov;52(5):829-38.

19.

Thioctic acid protects against carrageenan-induced acute inflammation in rats by reduction in oxidative stress, downregulation of COX-2 mRNA and enhancement of IL-10 mRNA.

El-Shitany NA, El-Masry SA, El-Ghareib MA, El-Desoky K.

Fundam Clin Pharmacol. 2010 Feb;24(1):91-9. doi: 10.1111/j.1472-8206.2009.00744.x. Epub 2009 Sep 3.

PMID:
19735303
20.

Supplemental Content

Support Center